Respiratory Medicine and Research最新文献

{"title":"Endobronchial valve (EBV) insertion for severe emphysema does not improve skeletal muscle mass or function: A pilot study on 19 patients","authors":"Julia Rubenstein ,&nbsp;Ilyès Benlala ,&nbsp;Emilie Mesa ,&nbsp;Anne-Claire Toublanc ,&nbsp;Marina Gueçamburu ,&nbsp;Arnaud Maurac ,&nbsp;Claire Bon ,&nbsp;Charlotte Vergnenegre ,&nbsp;Léo Grassion ,&nbsp;Geoffroy Moucheboeuf ,&nbsp;Patrick Dehail ,&nbsp;Gaël Dournes ,&nbsp;Maéva Zysman ,&nbsp;Pauline Henrot","doi":"10.1016/j.resmer.2025.101178","DOIUrl":"10.1016/j.resmer.2025.101178","url":null,"abstract":"<div><div>Endobronchial valve (EBV) insertion for severe emphysema allows to reduce hyperinflation and alleviates respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD). However, few studies investigate its effect on extra-pulmonary manifestations. We sought to assess the effect of EBV insertion on skeletal muscle mass and function, as well as determine if skeletal muscle parameters could represent a prognostic factor for response to EBV insertion.</div><div>We conducted a monocentric prospective pilot study including 19 patients. Exhaustive evaluation of lung &amp; skeletal muscle parameters was performed at baseline and 3 and 6 months after EBV insertion. Our primary aim was to assess the 6-month change in skeletal muscle parameters i.e. assessment of body composition with bioimpedance analysis (appendicular skeletal muscle mass index, fat mass, phase angle), evaluation of thoracic muscles (pectoralis, erector spinal, 5th intercostalis, psoas) surfaces and densities on CT-scans, and of upper limb force with handgrip test.</div><div>EBV insertion led to a significant improvement of lung function after 3 months and persisting at 6 months. In contrast, no significant improvement was observed in skeletal muscle parameters. In addition, no muscle parameter nor sarcopenic status was found to predict response to EBV insertion.</div><div>These results suggest that EBV insertion is not associated with strong systemic effects in our study, as well as emphasize the need to find bottom-up drug strategies for COPD-associated sarcopenia.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101178"},"PeriodicalIF":2.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological disparities in pulmonary sarcoidosis between public and private healthcare sectors in haute-Garonne department (France).","authors":"Nicolas Le Divenah, Grégoire Prévot, Aurélie Le Borgne, Florence Lintz, Gisèle Mourin, Pierre-Jean Esquerre, Jean-Christophe Aubry, William Heurtaux, Laura Petrov, Emilie Bousquet, Myriam Delaunay, Guillaume Faviez, Meritxell Pasto-Catusse, Jean-Marc Vernejoux, Marie-Christine Pujazon, Romain Barthes, Alain Didier, Julien Mazières, Nicolas Guibert, Thomas Villeneuve","doi":"10.1016/j.resmer.2025.101177","DOIUrl":"https://doi.org/10.1016/j.resmer.2025.101177","url":null,"abstract":"<p><strong>Introduction: </strong>Sarcoidosis is a multisystem granulomatous disorder that affects mediastinal and pulmonary structures in nearly 90% of cases. Given the high prevalence of respiratory involvement, pulmonologists are crucial in managing the disease, from diagnosis through to follow-up. In France, epidemiological data on sarcoidosis are limited, despite notable regional and international variations in the incidence and prevalence of the disease.</p><p><strong>Materials and methods: </strong>The SARCOPIDEMIO study is a prospective, multicenter observational study designed to estimate the incidence and prevalence of pulmonary sarcoidosis in the Haute-Garonne department (France). A total of 55 pulmonologists, representing both hospital-based and private practices, were invited to participate.</p><p><strong>Results: </strong>A total of 172 patients were included in the analysis. The minimal and estimated prevalence rates were determined to be 14.8 to 29.6 cases per 100,000 inhabitants, respectively. The incidence rate was 3.6 new cases per 100,000 inhabitants per year. Histological confirmation of granuloma was obtained in approximately 78% of the patients. Half of the patients received corticosteroid therapy, while one-quarter were treated with second-line immunosuppressive agents. The distribution of patients between public and private sectors was relatively balanced; however, multisystemic clinical presentations and the need for treatment were more frequently observed in hospital settings.</p><p><strong>Conclusion: </strong>The epidemiological data on pulmonary sarcoidosis from the Haute-Garonne department are relatively with those previously reported in France. Although sarcoidosis is a rare disease, its management is shared by all pulmonologists in our region.</p>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"101177"},"PeriodicalIF":1.8,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute effects of fan therapy on exercise-induced breathlessness in healthy adults and people living with chronic respiratory disease: A systematic review","authors":"Julien Da Purificaçao ,&nbsp;Clémence Pierret ,&nbsp;Tristan Bonnevie ,&nbsp;William Poncin","doi":"10.1016/j.resmer.2025.101172","DOIUrl":"10.1016/j.resmer.2025.101172","url":null,"abstract":"<div><h3>Background</h3><div>Exercise-induced breathlessness is a common complaint in the general population and a highly prevalent symptom in adults living with chronic diseases, often acting as an important barrier to engaging in physical activity. Fan therapy can reduce breathlessness at rest, yet its acute effects during exercise have not been systematically explored.</div></div><div><h3>Methods</h3><div>A literature search encompassing three electronic databases (PubMed, Scopus, Embase) from inception to January 2025 was conducted to identify randomized controlled trials comparing fan therapy during and after an acute exercise bout to a control condition, on dyspnea and exercise capacity. Relevant conference abstracts were considered. Risk of bias was assessed via the Physiotherapy Evidence Database scale. The PRISMA guidelines were followed.</div></div><div><h3>Results</h3><div>A total of six studies, including one conference abstract, met eligibility criteria. Five records involved 79 adults with chronic respiratory disease, all presenting a respiratory disease, and the remaining record included 10 healthy individuals. The results were generally consistent, showing that fan therapy significantly reduces exercise-induced breathlessness (<em>n</em> = 2 studies), decreases breathlessness during recovery (<em>n</em> = 5), and enhances exercise capacity (<em>n</em> = 2). The methodological quality was good for half or retrieved studies and poor-to-fair in the other half.</div></div><div><h3>Conclusion</h3><div>Fan therapy might relieve dyspnea and improve exercise capacity during and after an acute bout of exercise in patients with chronic respiratory disease. Future high-quality research should confirm these findings and consider assessing fan therapy effects in other populations. PROSPERO number: CRD42023475117</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101172"},"PeriodicalIF":2.2,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143947998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Mi-2 positive interstitial lung disease (ILD): A progressive disease comparable to other myositis-ILD","authors":"Bess M. Flashner ,&nbsp;Ryosuke Imai ,&nbsp;Andrew J. Synn ,&nbsp;Julia K. Munchel ,&nbsp;Lida P. Hariri ,&nbsp;Fiona K. Gibbons ,&nbsp;Sydney B. Montesi ,&nbsp;Barry S. Shea ,&nbsp;Mary B. Rice ,&nbsp;Rene S. Bermea ,&nbsp;Robert W. Hallowell","doi":"10.1016/j.resmer.2025.101176","DOIUrl":"10.1016/j.resmer.2025.101176","url":null,"abstract":"<div><h3>Background</h3><div>Evaluation for interstitial lung disease (ILD) often involves sending a myositis panel that includes myositis-associated and myositis-specific antibodies (MAA and MSA respectively) such as anti-Mi-2. Little is known about anti-Mi-2 positive ILD. We sought to determine the typical presentation and prognosis of anti-Mi-2 positive ILD.</div></div><div><h3>Methods</h3><div>We performed a retrospective chart review of patients in two ILD referral centers in Boston, MA with a positive anti-Mi-2 antibody between 2012 and 2024. Patients were identified by query of the medical record for patients with anti-Mi-2, and we included those with ILD on chest computed tomography (CT). We conducted survival analyses for ILD progression-free and overall survival using Kaplan-Meier curves and log-rank tests. Additionally, a Cox proportional-hazards model was employed, adjusting for age, gender, baseline forced vital capacity, and immunosuppressant use to calculate hazard ratios. The comparator group included patients who were followed longitudinally in the ILD clinic who were anti-Mi-2 negative but positive for other MSAs.</div></div><div><h3>Results</h3><div>Fifty-eight patients were identified. Half (52 %) were female with mean age 67 years (SD 13 years). The majority had dyspnea and/or cough, and a quarter of patients required oxygen upon presentation. Six (10 %) had PM/DM that pre-dated their ILD diagnosis. Other autoantibody positivity was common; one-third-of patients (<em>n</em> = 19, 33 %) were positive for anti-Mi-2 alone without positivity for other MSAs or MAAs. Clinical follow up data were available for 52 patients for a median follow up of 24 months (range &lt;1 month-10 years). PFT progression was seen in 67 % and radiologic progression was seen in over a third. Half received immunosuppression (55 %), with 19 % requiring multiple immunosuppressives. During follow up, 21 % had acute exacerbation of ILD or death. Progression-free and overall survival were not significantly different among anti-Mi-2 positive ILD <em>versus</em> anti-Mi-2 negative, MSA positive ILD patients regardless of anti-Mi-2 positivity alone or in combination with other autoantibodies.</div></div><div><h3>Conclusions</h3><div>This series of 58 patients is the largest anti-Mi-2 positive ILD cohort to date. Concurrent positivity with other autoantibodies associated with ILD was common. Anti-Mi-2 positive ILD was associated with similar outcomes to those with other MSAs. Larger studies are needed to better characterize patients with Mi-2 positive ILD.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101176"},"PeriodicalIF":2.2,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144177511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of cannabis smoking in patients with lung cancer: findings from KBP-CPHG-2020","authors":"Sébastien Couraud ,&nbsp;Olivier Molinier ,&nbsp;Marielle Sabatini ,&nbsp;Séverine Thomassin ,&nbsp;Rym Haouachi ,&nbsp;Virginie Levrat ,&nbsp;Hannah Ghalloussi-Tebai ,&nbsp;Antoine Belle ,&nbsp;Laurent Mosser ,&nbsp;Sébastien Larive ,&nbsp;Alexandra Bedossa ,&nbsp;Alexia Letierce ,&nbsp;Hugues Morel ,&nbsp;Didier Debieuvre ,&nbsp;Study Group KBP-2020-CPHG","doi":"10.1016/j.resmer.2025.101174","DOIUrl":"10.1016/j.resmer.2025.101174","url":null,"abstract":"<div><h3>Introduction</h3><div>Cannabis smoking is suspected to be a risk factor for lung cancer. The KBP-2020-CPHG study is a prospective study that collected data from all patients with newly diagnosed lung cancer in non-academic hospitals in France in 2020.</div></div><div><h3>Method</h3><div>We conducted comparative and matched cohort analyses using the dataset, in which cannabis smokers (i.e. participants who self-declared a lifetime intake of ≥20 joints) were compared with tobacco-only smokers. After matching on confounders, we compared age at diagnosis and overall survival.</div></div><div><h3>Results</h3><div>Among 8999 patients, 314 (3.6%) were cannabis smokers and 7372 were tobacco-only smokers (data missing for 183). Cannabis smokers were younger than tobacco-only smokers at lung cancer diagnosis (mean [± standard deviation] 52.9 [±8.84] <em>versus</em> 67.7 [±9.51] years; p&lt;0.0001), and this difference remained in the paired analysis (matched for histology, sex and cigarette pack-years [±5 pack-years]; n = 298 pairs; median age at diagnosis 53.1 <em>vs</em> 64.8 years; hazard ratio 5.61, 95% CI 4.10–7.68; p&lt;0.0001). Histological type was also different between the two groups, with more cases of adenocarcinoma and large cell neuroendocrine carcinoma among cannabis smokers. Finally, a 1:1 matched analysis controlled for age, sex, stage, histology and cigarette pack-years showed that overall survival was not affected by cannabis smoking (HR 0.90, 95% CI 0.68–1.18; p = 0.44).</div></div><div><h3>Conclusion</h3><div>We provide a detailed description of lung cancer characteristics among cannabis smokers compared with tobacco-only smokers. Cannabis smoking appeared to be associated with lung cancer diagnosis at an earlier age and was not a prognostic factor for mortality.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101174"},"PeriodicalIF":2.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of interstitial lung diseases in a native Afro-Caribbean population of French West Indies","authors":"Sylvain Neveu ,&nbsp;Milène Chaptal ,&nbsp;Elodie Rossigneux ,&nbsp;Hilario Nunes ,&nbsp;Chantal Raherison-Semjen","doi":"10.1016/j.resmer.2025.101175","DOIUrl":"10.1016/j.resmer.2025.101175","url":null,"abstract":"<div><h3>Introduction</h3><div>Data about interstitial lung diseases (ILDs) epidemiology in the Afro-Caribbean population is lacking. Differences in incidence and prevalence compared to European populations have already been reported. The main objective of this study was to estimate ILD incidence in Guadeloupe overall and by etiology. The secondary objective was to determine the clinical, demographic, and environmental characteristics of patients with ILD.</div></div><div><h3>Materials and methods</h3><div>We conducted a descriptive epidemiological study to estimate the incidence and prevalence of ILD in Guadeloupe between 2013 and 2019 and assess its etiological distribution.</div></div><div><h3>Results</h3><div>A total of 235 ILD cases in Guadeloupe were included. The incidence of ILD was 6.87 cases per 100,000 population per year, and the prevalence was 32.22 cases per 100,000 population. ILDs associated with connective tissue diseases accounted for 34 % of cases, with an incidence of 2.12 per 100,000 population. Sarcoidosis represented 31 % of cases, with an incidence of 1.72 per 100,000 population. Idiopathic ILDs made up 21 % of cases, with an incidence of 1.72 per 100,000 population. In this cohort, 25 % of patients were smokers, and 29 % of those with idiopathic pulmonary fibrosis (IPF) were farmers or agricultural workers.</div></div><div><h3>Conclusion</h3><div>We report the first study on ILD epidemiology in a native Afro-Caribbean population. Incidence and prevalence figures are lower than those previously reported in European populations. The main etiologies were connective tissue diseases, sarcoidosis, and idiopathic ILD.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101175"},"PeriodicalIF":2.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144231835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severe respiratory syncytial virus infection in older adults – burden, clinical outcomes and implications for care","authors":"Daniel Guimarães de Oliveira ,&nbsp;Ana Grande ,&nbsp;Francisco Belchior ,&nbsp;Rafaela Costa ,&nbsp;Rita Francisco ,&nbsp;Natália Oliveira ,&nbsp;Maria Calle","doi":"10.1016/j.resmer.2025.101173","DOIUrl":"10.1016/j.resmer.2025.101173","url":null,"abstract":"<div><h3>Background</h3><div>Respiratory syncytial virus (RSV) infection in adults remains under-researched. Increased testing is revealing an emerging picture of severe outcomes within the most prevalent lower respiratory tract infections. Understanding risk factors is increasingly important, especially in light of the recent approval of prophylactic vaccination.</div></div><div><h3>Methods</h3><div>Retrospective evaluation of all real-time polymerase chain reaction-positive RSV cases detected at our institution over three consecutive infection seasons from 2021 to 2024 in adults aged 60 years and older. Subsequent assessment of patients with severe infection requiring hospitalization.</div></div><div><h3>Results</h3><div>A total of 574 individuals were included, 57 % of whom were female, with a median age of 81,1 years (IQR 74–87 years). The peak number of cases occurred between September and March. We found a hospitalization rate of 51,2 % (representing an incidence of 1 case per 758 inhabitants per year in the elderly population of our region) and an in-hospital mortality rate of 15,6 % (19,1 % if transferred patients are excluded) among older adults with PCR-confirmed RSV infection. Heart failure (<em>p</em> ≤ 0.001), asthma (<em>p</em> = 0005), chronic kidney disease (<em>p</em> = 0006), chronic obstructive pulmonary disease (<em>p</em> = 0,02) and active smoking (<em>p</em> = 0.01) were risk factors for hospitalization. Older age (<em>p</em> = 0.003), residing in long-term care facility (<em>p</em> = 0.003), active cancer (<em>p</em> = 0,01), lower lymphocytes (<em>p</em> ≤ 0,001) and higher creatinine (<em>p</em> = 0,01) were significantly associated with mortality.</div></div><div><h3>Conclusions</h3><div>This is the first review of health outcomes related to RSV infection in the elderly from a Portuguese hospital. It identifies a high burden of hospitalization and in-hospital mortality in the elderly population. Our findings highlight the need for increased awareness of RSV infection in adults, particularly older adults, and underscore the importance of targeted interventions, such as vaccination programs, to reduce the burden of this disease in vulnerable populations in Portugal.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101173"},"PeriodicalIF":2.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolution of management in chronic thromboembolic pulmonary hypertension in a non-surgical / balloon pulmonary angioplasty center","authors":"Mitja Jevnikar,&nbsp;David Montani,&nbsp;Elie Fadel,&nbsp;Xavier Jais","doi":"10.1016/j.resmer.2023.101043","DOIUrl":"10.1016/j.resmer.2023.101043","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"87 ","pages":"Article 101043"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77233336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of inhaled corticosteroids on metabolic dysfunction-associated steatotic liver disease risk in COPD patients","authors":"Jiyu Sun ,&nbsp;Hyo Jin Lee ,&nbsp;Jung-Kyu Lee ,&nbsp;Tae Yeon Park ,&nbsp;Eun Young Heo ,&nbsp;Deog Kyeom Kim ,&nbsp;Hyun Woo Lee","doi":"10.1016/j.resmer.2025.101171","DOIUrl":"10.1016/j.resmer.2025.101171","url":null,"abstract":"<div><h3>Background</h3><div>The systemic impact of long-term use of inhaled corticosteroid (ICS) on the liver remains poorly understood in patients with chronic obstructive pulmonary disease (COPD). Our study aimed to identify whether long-term ICS therapy impacts the risk of Metabolic dysfunction-associated steatotic liver disease (MASLD) in patients with COPD.</div></div><div><h3>Methods</h3><div>A retrospective cohort study was conducted using claims records from a large population-based database. We included COPD patients ≥40 years old who had no previous history of chronic liver disease. Patients were divided into two groups based on their ICS use. The primary outcome was the development of MASLD. Additionally, subgroup analyses were conducted according to the duration of ICS exposure and the various components of ICS.</div></div><div><h3>Results</h3><div>A total of 442,880 COPD patients were included in the study, with 95,695 in ICS group and 347,185 in non-ICS group. The incidence rate of MASLD was higher in the ICS group compared to the non-ICS group (859.3 vs<em>.</em> 440.4 per 100,000 person-years). After adjusting for potential confounding factors, ICS use was associated with a significantly increased risk of MASLD (hazard ratio [HR]=1.630, 95 % confidence interval [CI]=1.560–1.704). Fluticasone furoate showed a higher risk of MASLD compared to other ICS components, and a longer duration of ICS exposure was associated with an increased MASLD risk.</div></div><div><h3>Conclusions</h3><div>In COPD patients, long-term use of ICS may be associated with an increased risk of developing MASLD. Further studies are needed to explore strategies to mitigate the potential risk of MASLD in COPD patients requiring ICS therapy.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"87 ","pages":"Article 101171"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143907710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update of guidelines for management of Community Acquired pneumonia in adults by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF)","authors":"Aurélien Dinh ,&nbsp;François Barbier ,&nbsp;Jean-Pierre Bedos ,&nbsp;Mathieu Blot ,&nbsp;Vincent Cattoir ,&nbsp;Yann-Erick Claessens ,&nbsp;Xavier Duval ,&nbsp;Pierre Fillâtre ,&nbsp;Maxime Gautier ,&nbsp;Yann Guegan ,&nbsp;Sophie Jarraud ,&nbsp;Alban Le Monnier ,&nbsp;David Lebeaux ,&nbsp;Paul Loubet ,&nbsp;Constance de Margerie ,&nbsp;Philippe Serayet ,&nbsp;Yacine Tandjaoui-Lambotte ,&nbsp;Emmanuelle Varon ,&nbsp;Yves Welker ,&nbsp;Damien Basille","doi":"10.1016/j.resmer.2025.101161","DOIUrl":"10.1016/j.resmer.2025.101161","url":null,"abstract":"<div><div>Community-Acquired Pneumonia (CAP) of Presumed Bacterial Origin: Updated Management Guidelines</div><div>Community-acquired pneumonia (CAP) of presumed bacterial origin is a common condition with varying severity, requiring either outpatient, hospital, or even critical care management.</div><div>The French Infectious Diseases Society (SPILF) and the French Language Pulmonology Society (SPLF), in collaboration with the French Societies of Microbiology (SFM), Emergency Medicine (SFMU), Radiology (SFR), and Intensive Care Medicine (SRLF), along with representatives of general practice, have coordinated an update of the previous management guidelines, which dated back to 2010.</div><div>From a therapeutic perspective, the updated recommendations define the choice of initial empiric antibiotic therapy, indications for combination therapy, the use of anti-Pseudomonas beta-lactams, antibiotic treatment duration, and the indications and modalities for prescribing systemic corticosteroids.</div><div>On a biological level, indications for biomarkers and microbiological investigations have been refined. Regarding imaging, the role of different modalities in the diagnosis and follow-up of CAP has been reassessed, including chest X-ray, pleuropulmonary ultrasound, and thoracic CT scan</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"87 ","pages":"Article 101161"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143558454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}